Reversible phosphorylation plays a critical role in DNA repair. Here we report the results of a loss-of-function screen that identifies the PP2A heterotrimeric serine/threonine phosphatases PPP2R2A, PPP2R2D, PPP2R5A and PPP2R3C in double-strand break (DSB) repair. In particular, we found that PPP2R2A-containing complexes directly dephosphorylated ATM at S367, S1893, and S1981 to regulate its retention at DSB sites. Increased ATM phosphorylation triggered by PPP2R2A attenuation dramatically upregulated the activity of the downstream effector kinase CHK2, resulting in G1/S phase cell cycle arrest and downregulation of BRCA1 and RAD51. In tumor cells, blocking PPP2R2A thereby impaired the high-fidelity homologous recombination repair pathway and sensitized cells to small molecule inhibitors of poly(ADP-ribose) polymerase (PARP). We found that that PPP2R2A was commonly downregulated in non-small cell lung carcinomas, suggesting that PPP2R2A status may serve as a marker to predict therapeutic efficacy to PARP inhibition. In summary, our results deepen understanding of the role of PP2A family phosphatases in DNA repair and suggest PPP2R2A as a marker for PARP inhibitor responses in clinic.
Introduction
Genome stability is essential for the prevention of undue cellular death and cancer development. To maintain genome integrity, cells have evolved multiple DNA repair pathways (1) . One of the most powerful activators of the DNA repair response is double-strand breaks (DSB).
Initiation of DSB repair is controlled by the phosphatidylinositol 3 kinase-like kinase (PIKK) family. A wave of phosphorylation events radiating from PIKKs is amplified to convey the signals to a large number of substrates. Although this cascade has been studied in a great detail, the biological relevance of many of these phosphorylation events and the mechanisms that control their down-regulation remain unknown (2) . It is conceivable that Ser/Thr protein phosphatases could be responsible for keeping proteins involved in DNA repair response in an inactive state under normal conditions or for inactivating the signaling once DNA has been repaired. However, phosphorylation of a number of PIKKs, including ataxia telangiectasia mutated (ATM), ATR, and CHK2, oscillates during the DNA repair process (3, 4) , suggesting that phosphatases may serve not only as negative regulators but also as active modulators of DNA damage response.
Protein phosphatase 2A (PP2A) refers to a large family of heterotrimeric Ser/Thr phosphatases. The PP2A core enzyme consists of a catalytic C subunit and a structural A subunit. In mammals, two distinct genes encode closely related versions of both the PP2A A (Aα/PPP2R1A and Aβ/PPP2R1B) and C (Cα/PPP2CA
and Cβ/PPP2CB) subunits. The AC dimer recruits a third, regulatory B subunit, which is responsible for the substrate specificity and function of the PP2A heterotrimeric Approximately 100 distinct complexes can be formed through combinatorial association of these subunits, and it is believed that specific PP2A complexes mediate particular physiological functions (5, 6) .
PP2A has been directly implicated in the negative regulation of DSB DNA repair proteins, including γH2AX, ATM, CHK1, and CHK2 (2) . However, consistent with the idea that protein phosphatases are not just negative regulators of DNA repair signaling, selective inhibition of PP2A activity impairs DNA repair (7) (8) (9) . PP2A function is also essential for activation of cell cycle checkpoints in response to IR (10, 11) . One potential explanation for this apparent discrepancy is that several distinct PP2A complexes may modulate different steps of the DNA repair process.
Here we assessed the role of specific PP2A complexes in control of DSB repair and identify PPP2R2A as a critical effector of the homologous recombination (HR) repair through modulation of ATM phosphorylation. Critically, defects of HR DNA repair in PPP2R2A-depleted cells dramatically increased their sensitivity to poly(ADP-ribose) polymerase (PARP) enzyme inhibition. Finally, we show that PPP2R2A is commonly down-regulated in non-small cell lung carcinomas (NSCLCs) and therefore propose PPP2R2A status as a predictive marker for sensitivity to PARP inhibition. and phosphatase inhibitor cocktails (Roche). The cell lysates were incubated on ice for 10 minutes and then centrifuged at 500 x g for 5 minutes at 4°C. The supernatant and pellet were designated as cytoplasmic and nuclear fractions, respectively. The nuclear fraction was resuspended in 10 mM NaCl, 5 mM MgCl 2 , 250 mM sucrose, 1 mM EGTA, 10 mM Tris-HCl pH 7.6 containing protease and phosphatase inhibitor cocktails and treated with RNase-free DNase I (80 μg/mL; Roche) for 30 minutes at 37°C.
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The following antibodies were used: goat polyclonal anti-ATM, (Novus Biologicals), mouse monoclonal anti-PP2AC (BD Biosciences, clone 46), mouse monoclonal anti-BRCA1 (Santa Cruz, clone D-9). The following antibodies were purchased from Cell Signaling: rabbit polyclonal anti-Flag; rabbit polyclonal antiphospho-CHK1 (S296); rabbit polyclonal anti-phospho-CHK2 (T68); rabbit polyclonal anti-phospho BRCA1 (S1524); rabbit polyclonal anti-CDC25A; rabbit polyclonal anti-PPP2R2A; mouse monoclonal anti-phospho-ATM (S981) (clone 10H11.E12), mouse monoclonal anti-CHK2 (clone 1C12); mouse monoclonal anti-PP2A A (clone 4G7), and; rabbit polyclonal anti-phospho-CHK1 (S317); rabbit monoclonal anti-phospho-CHK1 (S345) (clone 133D3). Microscope slides were pre-coated with a thin layer of normal melting point agarose. Cell suspensions were placed into a tube containing low melting point agarose and transferred to a glass microscope slide. Slides were placed in 2 M NaCl, 30 mM Na 2 EDTA, 10 mM Tris-HCl, 1% Triton X-100 and 10% DMSO, pH 8.0 for 1 hour at 4°C. After lysis, the slides were rinsed for 20 minutes in solution 0.3 M NaOH, 1mM EDTA and were subjected to electrophoresis at 0.7 V/cm and 50 mA for 20 minutes. The slides were then rinsed with 1 M Tris-HCl, pH 7.5 and dried with prechilled absolute ethanol and stained with PI (2μg/ml). Comet images were examined at 200×magnification with Nikon ECLIPSE Ti microscope. The tail moment values were quantified by CometScore software v1.5.
Neutral comet assay

Immunofluorescent microscopy
Cells were plated on cover slips or μClear-96 well plates (Greiner Bio-One) and fixed with 4% paraformaldehyde for 10 minutes at RT and permeabilized with ice-cold methanol for 5 minutes at -20°C. The cells were incubated in blocking buffer 3% bovine serum albumin (BSA) in PBS for 30 minutes at RT and then with primary antibodies. After three washes with 0.3% BSA in PBS, the secondary antibody was added. The following antibodies were used: mouse monoclonal anti-γH2AX (S139) (Millipore, clone JBW301), mouse monoclonal anti-RAD51 (Abcam, clone 14B4).
Automated Image analysis was performed using IN Cell Analyzer 2000 (GE Healthcare) (Suppl. Figure 1,2) .
Quantitative real-time reverse-transcription PCR (qRT-PCR)
Total RNA was isolated using RNeasy (Qiagen), and cDNA was synthesized using the Advantage RT-PCR kit (Clontech). A list of primers used for real-time qPCR is presented in Suppl. Figure 3A . Real-time PCRs were conducted in a Roche
LightCycler-480-96 (Roche), using SYBR Green PCR Master Mix (Roche).
qRT-PCR analysis of The Lung Cancer cDNA and Cancer Survey cDNA arrays (OriGene) was performed using an ABI 7500 (Applied Biosystems).
NHEJ and HR DNA repair assays
Non-homologous end joining (NHEJ) repair efficiency was analyzed using 
Clonogenic survival assay and cell viability
Results
Identification of PP2A specific complexes involved in DSB repair
Although previous studies demonstrated that PP2A negatively regulates PIKKinduced signaling, more recent reports have shown that PP2A inhibition impairs DNA repair (7, 8) . To further investigate this apparent conundrum, we silenced the more abundant PP2A catalytic subunit, PPP2CA. Because cells expressing very low levels of PPP2CA proliferate poorly (14, 15), we used shRNAs that only partially suppress PPP2CA expression ( Figure 1A ). Consistent with a previous report (7), both immunoblot analysis of γH2AX and automatic image analysis of γH2AX immunostaining revealed that partial depletion of PPP2CA resulted in inefficient DNA repair ( Figure 1A ,B).
To systematically identify PP2A complexes that mediate DSB repair, we performed a loss-of-function screen using shRNA library that targets each of the known PP2A B regulatory subunits (16) . qRT-PCR analysis confirmed the knockdown (KD) in each of the shRNA-expressing cell lines ( Figure 1C , Suppl. Figure 3B ). Whenever specific antibodies were available, we also confirmed silencing of the PP2A subunits by immunoblotting (Suppl. Figure 3C ).
In addition to PPP2CA, we found that suppression of four PP2A regulatory subunits, PPP2R2A, PPP2R2D, PPP2R5A, and PPP2R3C, resulted in a statistically significant (p<0.05 by Student's t test) increase of γH2AX compared to cells expressing shGFP ( Figure 1C ). For PPP2R5B and STRN3 subunits, only expression of one out of two shRNAs resulted in γH2AX increase, most probably due to off-target effects ( Figure 1C PPP2R2A, PPP2R2D, PPP2R5A, and PPP2R3C, could be involved in control of DSB repair.
PPP2R2A is commonly down-regulated in NSCLCs
Inefficient DNA repair mediated by suppression of specific PP2A B subunits suggests the contribution of these PP2A subunits to tumor suppression. In consonance with this idea, recent analysis of outlying expression coincident with extreme copy number alterations has identified PPP2R2A, one of our hits, as a putative tumor suppressor gene in breast cancer (17) . Moreover, high-resolution analyses of somatic copy-number alterations of large-scale datasets revealed statistically significant loss-of-heterozygosity (LOH) of the PPP2R2A-containing region in human cancers (18, 19) . Reduced PPP2R2A mRNA expression was also found in prostate adenocarcinoma samples (20, 21) . with known status of PPP2R2A LOH (Suppl. Figure 4C ). In fact, immunoblot analysis of PPP2R2A expression revealed lower levels of PPP2R2A in cell lines harboring PPP2R2A LOH ( Figure 2C) . A common down-regulation of PPP2R2A in NSCLCs due to LOH of PPP2R2A-containing region further support the idea that PPP2R2A functions as a tumor suppressor. Thus, our further studies were focused on PPP2R2A.
PPP2R2A inhibits the HR repair by affecting cell cycle progression in response to DNA damage
We validated the results of the loss-of-function screen by analyzing γH2AX after PPP2R2A suppression at different time points following IR or bleomycin treatment ( Figure 3A,B) . Moreover, overexpression of shRNA resistant form of PPP2R2A in PPP2R2A KD cells restored γH2AX levels ( Figure 3C ), indicating that inefficient DSB repair is triggered specifically by loss of PPP2R2A. Single-cell gel electrophoresis also revealed that unresolved DNA damage induced by camptothecin was significantly higher in PPP2R2A KD cells ( Figure 3D ). Taken together, our observations strongly support the idea that PPP2R2A plays a key role in DSB DNA repair.
To assess a possible mechanism by which PPP2R2A modulate DSB repair, we elucidated the effect of PPP2R2A suppression on two major pathways of DSB repair, NHEJ and HR (22, 23) . We found that although suppression of PPP2R2A facilitated the NHEJ repair, the HR pathway was dramatically inhibited in PPP2R2A KD cells ( Figure 4A,B) . Consistently, we found a decreased Rad51 foci formation in cells expressing shPPP2R2A ( Figure 4C ; Suppl. Because the balance between NHEJ and HR repair depends on the phase of cell cycle (22, 24) , we examined the effect of PPP2R2A on IR-induced cell cycle checkpoints. We found that 8 hours after IR, HeLa cells expressing shGFP accumulated in G2/S phase, whereas cells with suppressed PPP2R2A were mostly in the G1 phase of the cell cycle ( Figure 4E,F) . In addition, BrdU incorporation after IR was dramatically decreased in PPP2R2A KD cells ( Figure 4G ). We also observed that I-SceI-induced DSBs resulted in accumulation of 293DR-GFP-shPPP2R2A cells in the G1 phase of the cell cycle ( Figure 4H ). In concordance with these results, we found that in response to IR expression of the cell cycle-promoting phosphatase CDC25A (25) was significantly decreased in PPP2R2A-depleted cells ( Figure 4I ).
Taken together, these data indicate that PPP2R2A modulates the HR repair through regulation of G1/S cell cycle checkpoint. Accelerated Cdc25A turnover after DNA damage is regulated by the CHK1 and CHK2 kinases (26, 27) . Therefore, we analyzed the effect of PPP2R2A on CHK1 or CHK2 activation. Although inhibition of PPP2R2A did not affect CHK1 phosphorylation at S296, S217, and S345, we observed a significant accumulation of CHK2 phosphorylated at T68 in PPP2R2A KD cells ( Figure 4I ), suggesting that G1/S checkpoint induced by loss of PPP2R2A is mediated by prolonged activation of the CHK2 kinase. 
PPP2R2A directly regulates ATM phosphorylation
CHK2 is a direct downstream target of ATM, while ATM has been shown to be directly regulated by PP2A. In particular, a previous report (28) reveals that a specific PP2A inhibitor, okadaic acid, induces ATM autophosphorylation at S1981. Moreover, the authors demonstrated interaction between ATM and PP2A A and C subunits.
However, specific PP2A regulatory subunit(s) involved in ATM dephosphorylation has not been identified, whereas our data suggest that PPP2R2A may affect CHK2 activity by regulating ATM dephosphorylation.
Indeed, we found that suppression of PPP2R2A resulted in a significant increase of ATM phosphorylated at S1981 ( Figure 5A ), while restoration of PPP2R2A expression by overexpression of shRNA-resistant silent mutant of PPP2R2A rescued this increase ( Figure 4B ). Although ATM phosphorylation is considered as a sign of ATM activation, there are contradictory data how it affects ATM functions.
Studies of ATM-S1987A (mouse homologue of human S1981) mice demonstrated normal ATM-dependent phosphorylation of ATM substrates, activation of cell cycle checkpoints, and localization of ATM to DSBs (29, 30) . In vitro studies using human recombinant ATM proteins revealed that phosphorylation does not affect its kinase activity (31) (32) (33) . In human cells ATM phosphorylation at S1981 is also dispensable for the ability of ATM to localize to DSBs, but it is required for ATM retention at DSBs (34) . Consistently with this report, immunofluorescent analysis of ATM revealed an increase of the size of ATM foci in PPP2R2A KD cells ( Figure 5C ), further confirming the idea that phosphorylation regulates ATM retention at the sites of DSBs (34).
These findings suggest that PPP2R2A controls DNA repair through regulation of the ATM signaling. To test this hypothesis, we analyzed whether PPP2R2A affects DNA repair in HeLa ATM SilenciX (ATM KD) cells. Indeed, analysis of γH2AX levels in ATM-deficient cells revealed that suppression of PPP2R2A in these cells did not affect the kinetics of DNA repair ( Figure 5D ).
To determine whether PPP2R2A directly regulates ATM dephosphorylation, we performed a set of reciprocal immunoprecipitations. We found PPP2R2A together with PP2A A and C subunits in complex with ATM ( Figure 6A ). Using in vitro phosphatase assays, we also found that phosphopeptides corresponding to human ATM pS367, pS1893, and pS1981, but not pT1885 and pS2996, were efficiently dephosphorylated by PPP2R2A specific complexes ( Figure 6B ). Given that we observed an interaction between PPP2R2A heterotrimeric complexes and ATM, increased ATM phosphorylation in PPP2R2A-depleted cells, and in vitro dephosphorylation of three ATM autophosphorylation sites (S367, S1893, and S1981) by PPP2R2A-specific complexes, it seems likely that ATM is a direct target for PPP2R2A-specific PP2A phosphatase in vivo.
Wip1 phosphatase has been also demonstrated to dephosphorylate ATM at S1981 and S367, but not at S1893 (35, 36) (Figure 6B complexes. Consistently with this report, 15 minutes after IR PPP2R2A associated phosphatase activity was decreased. 30 minutes after IR PPP2R2A was found again in complex with ATM, which is also correlated with an increase of PPP2R2A-specific phosphatase activity towards ATM phosphopeptides ( Figure 6D,E) . This kinetics is consistent with the kinetics of ATM recruitment/dissociation to the sites of DSBs (34) .
These data also suggest the existence of a negative-feedback loop between PPP2R2A and ATM.
PPP2R2A down-regulation increases sensitivity to PARP inhibitors
Inhibition of the HR repair in PPP2R2A-depleted cells suggest that these cells are highly sensitive to DNA damage. Indeed, colony formation assay revealed that inhibition of PPP2R2A sensitized cells to IR ( Figure 7A ). Moreover, HR deficiency predicts hypersensitivity to inhibition of poly(ADP-ribose) polymerase (PARP) (38, 39) . In fact, analysis of cell survival after treatment with ABT-888 (veliparib), a potent inhibitor of PARP1 and PARP2, revealed that PPP2R2A KD cells are more sensitive to ABT-888 treatment ( Figure 7B ). To validate this observation, we examined the sensitivity to PARP inhibition of lung carcinoma cell lines with different levels of PPP2R2A expression. Consistently, we found that cell lines with higher PPP2R2A expression had lower sensitivity to ABT-888 compared to cell lines with lower PPP2R2A expression ( Figure 2C, 7C) . ABT-888 treatment also inhibited growth of PPP2R2A KD A549 xenografts ( Figure 7D ). Moreover, we observed significantly reduced proliferation rate and increased apoptosis in PPP2R2A KD tumors compared to shGFP expressing tumors ( Figure 7E,F) . These results strongly indicate that both PPP2R2A expression levels and LOH in the PPP2R2A-containing region can be used to predict tumor sensitivity to treatment with PARP inhibitors. 
Discussion
PP2A is a ubiquitously expressed family of Ser/Thr protein phosphatases, and the diversity of PP2A functions suggests that particular PP2A complexes may contribute independently to complex phenotypes, such as the DNA damage response (5, 6) . Indeed, we found that suppression of four different PP2A regulatory B subunits (PPP2R2A, PPP2R2D, PPP2R5A, and PPP2R3C) impairs the efficiency of DNA repair, suggesting that these specific PP2A complexes are involved in control of DNA repair. In our prior study, we performed a loss-of-function screen using a similar shPP2A library to identify PP2A subunits involved in human cell transformation (16) . This screen implicates three PP2A regulatory subunits, PPP2R5A, PPP2R5C, PPP2R3A, in control of cell transformation. Our present results suggest that in addition to modulating c-Myc and Wnt activity (16), PPP2R5A could also contribute to the tumorigenic phenotype by impairing DNA repair efficiency. Consistent with this idea, it has been shown that PPP2R5A could directly dephosphorylate both c-Myc (40) and CHK2 kinase (41) . However, the exact mechanism(s) by which PPP2R2D, PPP2R5A, and PPP2R3C contribute to DNA response needs to be further investigated.
In summary, our study revealed that dephosphorylation of ATM at S367, S1893, and S1981 by PPP2R2A-specific complexes regulates retention of ATM foci. 
Grant Support
This work was supported by FWO (ZKC2592-00_WO1), and a Distinguished Young Scholar of National Nature Science Foundation of China NSFC 30925029). 0 18% 36% 75% 85% 73% 62% 60% 53% 70% 85% 60% 56% 70% 59% 63% 72% 60% 53% 77% 70% 97% 75% 92% 91% 70% 60% -----+ + + + + + 
